drugset / Trial / NCT02115048

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

NCT02115048

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare the efficacy of treatment with afatinib plus letrozole to treatment with letrozole alone in women diagnosed with a specific type of breast cancer.

Timeline

Start
2014-07
Primary completion
2018-11
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 30 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications